ArticleJournal of obesity2011
Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia.
Article in Journal of obesity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Weight management interventions for adults living with overweight or obesity and severe mental illness: a systematic review and meta-analysis.The British journal of nutrition · 2023Pooled it
- Diabetes Mellitus in Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Prevalence of Types and Risk Factors.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel.Therapeutic advances in psychopharmacology · 2018Review
- Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.Neuropsychiatric disease and treatment · 2017Review
- Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.International clinical psychopharmacology · 2015Article
- Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada.Frontiers in psychiatry · 2014Article
- Behavioral interventions for antipsychotic induced appetite changes.Current psychiatry reports · 2013Article
- Role of aripiprazole in treatment-resistant schizophrenia.Neuropsychiatric disease and treatment · 2012Article
- Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Weight gain is one of the major drawbacks associated with the pharmacological treatment of schizophrenia. Existing strategies for the prevention and treatment of obesity amongst these patients are disappointing. Switching the current antipsychotic to another that may favorably affect weight is not yet fully established in the psychiatric literature. This meta-analysis focused on switching to aripiprazole as it has a pharmacological and clinical profile that may result in an improved weight control. Nine publications from seven countries worldwide were analyzed. These encompassed 784 schizophrenia and schizoaffective patients, 473 (60%) men and 311 (40%) women, mean age 39.4 ± 7.0 years. The major significant finding was a mean weight reduction by -2.55 ± 1.5 kgs following the switch to aripiprazole (P < .001). Switching to an antipsychotic with a lower propensity to induce weight gain needs be explored as a strategy. Our analysis suggests aripiprazole as a candidate for such a treatment strategy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.